Anja Borgmann

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Overview: In driving hES cell technology towards widespread applications considerable effort has been focused on the improvement of culture conditions and on enabling efficient differentiation. We have established two technologies which will better enable researchers to achieve these aims. The use of feeder based protocols for the creation, expansion and(More)
BACKGROUND Therapeutic use and effective function of recombinant urokinase (r-UK) for occluded ports need the presence of plasminogen. METHODS As a therapeutic proof of principle, we demonstrate that the use of r-UK and autologous plasma effectively reestablishes the function of occluded central venous ports (CVP) resistant to routine management of(More)
It is unclear how best to treat children with acute lymphoblastic leukaemia (ALL) who are in a second remission. Treatment with bone-marrow transplants from HLA-identical siblings results in a statistically greater likelihood of leukaemia-free survival than does chemotherapy. Less than 25% of relapsed patients are able to benefit from this therapy due to a(More)
  • 1